Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2013

View Archived Issues

Boehringer Ingelheim reports on BRAF inhibitor for the treatment of melanoma

Suzhou Kintor discovers novel androgen receptor antagonist

TransTech Pharma presents data on RAGE inhibitor for Alzheimer's disease

TY-032, a new analgesic peptide

Seikagaku commences phase III trial to treat lumbar disc herniation in the U.S.

Cytochrome P450 2W1 activates ICT-2706 against colon cancer

Isis Pharmaceuticals begins phase II study of ISIS-SMNRx in infants with SMA

Achillion provides updated results from phase II trial of ACH-3102

Addex gains clearance to conduct phase I trial of ADX-71441 in the Netherlands

Celsion describes company activity

Proteome Sciences offers multiple protein CSF biomarker assay for Alzheimer's disease

Elevated RBP4 plasma levels associated with impaired glucose metabolism in obese patients

Graft expression of HLA-G in LTx recipients as a predictive biomarker of lower risk of BOS

Preclinical evidence supporting antisense oligonucleotide therapy to treat hearing disorders

Corgenix reports progress in collaborative efforts to detect Lassa hemorrhagic fever

Theradiag receives CE mark for anti-CCP in vitro diagnostic kit

Novel ACE inhibitors created at Morinaga Milk Industry

Diamyd Medical to change name

OPKO Health signs merger agreement with Prolor Biotech

Presage Biosciences begins trial of CIVO precision oncology platform

Tranzyme Pharma and Ocera Therapeutics enter into a merger agreement

Chinese company patents novel oxazolidinones

Research at Sanofi yields new PKC beta 2 inhibitors

Researchers at Bristol-Myers Squibb disclose novel NR2B antagonists

Japan Tobacco subsidiary set to launch novel anti-HIV combination tablet in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...